ArticleBMC immunology2012
Functional requirements for inhibitory signal transmission by the immunomodulatory receptor CD300a.
Article in BMC immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Spatial Transcriptomics of Human Decidua Identifies Molecular Signatures in Recurrent Pregnancy Loss.Genomics, proteomics & bioinformatics · 2026Article
- CD300a: An Innate Immune Checkpoint Shaping Tumor Immunity and Therapeutic Opportunity.Cancers · 2025Review
- Small molecules as ligands in the tuning of immune regulatory receptors.Frontiers in immunology · 2025Review
- Multi-modal analysis reveals tumor and immune features distinguishing EBV-positive and EBV-negative post-transplant lymphoproliferative disorders.Cell reports. Medicine · 2024Article
- Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies.Cancer biology & medicine · 2024Article
- Human IgMInternational journal of molecular sciences · 2023Article
- Inflammatory Cytokines That Enhance Antigen Responsiveness of Naïve CD8International journal of molecular sciences · 2022Article
- CD300a contributes to the resolution of articular inflammation triggered by MSU crystals by controlling neutrophil apoptosis.Immunology · 2021Article
- The Expression and Function of CD300 Molecules in the Main Players of Allergic Responses: Mast Cells, Basophils and Eosinophils.International journal of molecular sciences · 2020Review
- Altered Expression of CD300a Inhibitory Receptor on CD4+ T Cells From Human Immunodeficiency Virus-1-Infected Patients: Association With Disease Progression Markers.Frontiers in immunology · 2018Article
- Differential Effect of Cytomegalovirus Infection with Age on the Expression of CD57, CD300a, and CD161 on T-Cell Subpopulations.Frontiers in immunology · 2017Article
- Immunoreceptors on neutrophils.Seminars in immunology · 2016Review
- Synovial fluid proteome in rheumatoid arthritis.Clinical proteomics · 2016Article
- Role of phosphatidylserine receptors in enveloped virus infection.Journal of virology · 2014Article
- Review
- CD300c is an activating receptor expressed on human monocytes.Journal of innate immunity · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundActivation signals can be negatively regulated by cell surface receptors bearing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). CD300a, an ITIM bearing type I transmembrane protein, is expressed on many hematopoietic cells, including subsets of lymphocytes.
resultsWe have taken two approaches to further define the mechanism by which CD300a acts as an inhibitor of immune cell receptor signaling. First, we have expressed in Jurkat T cells a chimeric receptor consisting of the extracellular domains of killer-cell immunoglobulin-like receptor (KIR)2DL2 fused to the transmembrane and cytoplasmic segments of CD300a (KIR-CD300a) to explore surrogate ligand-stimulated inhibition of superantigen stimulated T cell receptor (TCR) mediated cell signaling. We found that intact CD300a ITIMs were essential for inhibition and that the tyrosine phosphorylation of these ITIMs required the src tyrosine kinase Lck. Tyrosine phosphorylation of the CD300a ITIMs created docking sites for both src homology 2 domain containing protein tyrosine phosphatase (SHP)-1 and SHP-2. Suppression of SHP-1 and SHP-2 expression in KIR-CD300a Jurkat T cells with siRNA and the use of DT40 chicken B cell lines expressing CD300a and deficient in several phosphatases revealed that SHP-1, but not SHP-2 or the src homology 2 domain containing inositol 5' phosphatase SHIP, was utilized by CD300a for its inhibitory activity.
conclusionThese studies provide new insights into the function of CD300a in tuning T and B cell responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.